Molefy Pharma Presents Its Strategy to Develop New Therapies for Neurodegenerative Diseases Such as ALS
The Spanish company combines pharmaceutical research and development with business capabilities to translate scientific knowledge into new therapeutic opportunities. AP-2, its most advanced program, currently in Phase I, is investigating a new approach to targeting TDP-43 protein dysfunction associated with ALS, with the aim of reversing or curing the disease. Dr. Ana Martínez and Dr. […]
Molefy Pharma’s Research Places the Canary Islands at the Heart of the Fight Against ALS
The company collaborated with Molefy Pharma, the CSIC and the Government of the Canary Islands in an event that brought together experts to address the scientific, care-related and social challenges of Amyotrophic Lateral Sclerosis.
What Happens Before a Clinical Trial Begins? Understanding the Development of New Therapies for ALS
What Happens Before a Clinical Trial Begins? Understanding the Development of New Therapies for ALS When the start of a clinical trial is announced, the news is often summarized in just a few words: “a new treatment enters Phase I.” Behind that moment, however, are years of research, regulatory evaluation, and a carefully designed sequence […]
Innovation in Biotechnology: How New Therapies for ALS Are Developed
When we talk about innovation in healthcare, we often think of major breakthroughs or singular discoveries. In reality, in diseases such as amyotrophic lateral sclerosis (ALS), innovation is often quieter. It is the result of many small steps that gradually reshape how we understand the disease and how we can address it. For years, progress […]
AEMPS authorizes the initiation of the clinical trial of AP-2, Molefy Pharma’s therapeutic candidate for ALS
AEMPS authorizes the initiation of the clinical trial of AP-2, Molefy Pharma’s therapeutic candidate for ALS • The AEMPS authorizes the initiation of the Phase I clinical trial of AP-2, which will begin in April at Hospital Universitario de La Princesa with 70 healthy volunteers • AP-2, developed by Molefy Pharma based on CSIC research, targets the TDP-43 […]
Clinical Trials in Spain: A Strategic Opportunity to Accelerate Innovation in ALS
The development of new therapies for amyotrophic lateral sclerosis (ALS) does not rely solely on advances in biomedical research at the laboratory level. It also requires the ability to translate that knowledge into the clinical setting in an efficient, safe, and coordinated way. In this context, clinical trials in Spain have become a fundamental pillar […]
The future of ALS research: why the coming years will be decisive
Amyotrophic lateral sclerosis (ALS) is one of the most complex and devastating neurodegenerative diseases of our time. For decades, biomedical research has progressed slowly, with limited therapeutic options and modest clinical impact. However, the landscape is changing. The coming years are shaping up to be a critical turning point for pharmaceutical research in ALS, driven […]
A Canary Islands Company Leads the Clinical Trial of a New Drug to Treat ALS
Following the discovery of several molecules by a CSIC research group, Molefy Pharma will become one of the first organizations worldwide to evaluate the viability of this new therapeutic approach. By Verónica Pavés. Santa Cruz de Tenerife. Originally published by El Día. A company based in the Canary Islands will lead the clinical trial of a promising new treatment aimed […]
Molefy Pharma receives Orphan Drug Designation (ODD) from the European Union for its AP-2 candidate in the treatment of amyotrophic lateral sclerosis (ALS)
The European Medicines Agency (EMA) has granted Molefy Pharma the Orphan Drug Designation (ODD) for its candidate AP-2, an innovative therapy developed for the treatment of amyotrophic lateral sclerosis (ALS). This designation is awarded to medicines with the potential to treat rare and severe diseases in the European Union, when they offer a significant benefit […]
ALS Association awards $1 million to Molefy Pharma to advance its clinical trial against ALS
Spanish biotech company receives backing from one of the leading global organizations in the fight against amyotrophic lateral sclerosis (ALS) ARQUIMEA, Spanish technology group and co-founder of the spin-off Molefy Pharma together with researchers from the CSIC, celebrates the award of a $1 million grant from the ALS Association (ALS.org) to accelerate the development of […]